Drug makers get sweeping immunity to pay patients into trials

What it does

This bill makes it easier for pharmaceutical and medical device companies to recruit and retain patients in clinical trials, especially from underrepresented populations. It does this by: (1) authorizing federal grants for community outreach and training to boost enrollment; (2) allowing companies to pay trial participants' travel, meals, and other expenses without triggering anti-kickback laws; (3) permitting companies to cover patients' insurance cost-sharing (copays, deductibles) during trials; and (4) making up to $2,000 per year in trial payments tax-free to participants. The bill frames these changes as diversity and access measures, but the primary beneficiaries are pharmaceutical and device manufacturers seeking to fill trials faster and cheaper.

Why we flagged it

While framed as a diversity and access measure, the bill's substantive mechanism is a broad exemption from anti-kickback and False Claims Act liability for pharmaceutical and device manufacturers paying patient expenses and cost-sharing during trials. This is functionally a regulatory carve-out that reduces compliance friction for an industry seeking to accelerate enrollment.

What the text implies

• Manufacturers gain financial leverage to preferentially enroll vulnerable or economically disadvantaged patients, potentially skewing trial demographics toward populations with fewer treatment alternatives and higher desperation to participate.
• The anti-kickback exemption (Section 4–5) is broadly written and may extend beyond the stated diversity purpose to routine trial recruitment, effectively narrowing enforcement of existing fraud statutes.
• Cost-sharing subsidies create a two-tier trial system: patients who can afford cost-sharing participate in standard trials; those who cannot are funneled into manufacturer-subsidized trials, potentially affecting data quality and generalizability.
• The $2,000 annual tax exclusion incentivizes longer trial participation and may discourage early withdrawal even if adverse events occur, as participants lose the tax benefit upon disenrollment.
• Federal grants (Section 3) flow to entities partnering with manufacturers, creating financial incentives for community organizations to prioritize enrollment over informed consent quality.

Who it affects

Patients in underrepresented communities gain improved access to trials and removal of financial barriers to participation, which is a genuine public health benefit. However, the bill's core mechanism—allowing manufacturers to subsidize patient costs without anti-kickback oversight—creates a financial incentive for companies to enroll sicker or more vulnerable patients, potentially increasing adverse event risk and reducing trial integrity. The $2,000 tax exclusion is a modest benefit to individ

Who stands to gain

• pharmaceutical manufacturers
• medical device manufacturers
• contract research organizations
• clinical trial recruitment firms

Named in the bill

National Institutes of Health, Food and Drug Administration, Centers for Medicare & Medicaid Services, Social Security Act Section 1128A (Civil Monetary Penalties Law), Social Security Act Section 1128B (Anti-Kickback Statute), False Claims Act, Internal Revenue Code Section 139J, Public Health Service Act Section 2709, Federal Food, Drug, and Cosmetic Act Sections 505 and 520, Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE) — and 2 more

Where it stands

30 cosponsors: 19 Democrats, 11 Republicans.

• May 20, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 20, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

15 lobbying clients named this bill on 22 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $18,511,988 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 95% of bills with at least one filing.

Raul Ruiz, the sponsor, reported $1,028,105 in PAC receipts in the 2026 cycle. $5,500 of that came from 2 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• Mckesson Corporation & Affiliates U.S. Oncology and Rx Savings Solutions — $1,710,000 on 2 filings
• Astrazeneca Pharmaceuticals Lp — $1,680,000 on 1 filing
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.